Ted Love

Ted W.
Love is Independent Director at Gilead Sciences, Inc. since 2024; Director at Biotechnology Innovation Organization starting 2025; Non-Executive Director at Avillion LLP since 2014; Independent Director at Structure Therapeutics, Inc. since 2023; Lead Independent Director at Royalty Pharma Plc starting 2025; Director at Life Science Cares Bay Area; and Independent Director at Jazz Pharmaceuticals Plc starting 2025.
Former roles include Chairman, President & Chief Executive Officer at Nuvelo, Inc. from 2001 to 2009; President, Chief Executive Officer & Director at Global Blood Therapeutics, Inc. from 2014 to 2022; Independent Director at Bio-Rad Laboratories, Inc. from 2011 to 2013; Independent Director at Seagen, Inc. from 2020 to 2023; Independent Director at Mast Therapeutics, Inc. from 2012 to 2013; Director at Anesiva, Inc.; Independent Director at Santarus, Inc. from 2011 to 2014; Independent Director at Amicus Therapeutics, Inc. from 2012 to 2020; Lead Independent Director at Humanigen, Inc. in 2015; Director at Predix Pharmaceuticals, Inc.; Independent Director at Portola Pharmaceuticals LLC from 2019 to 2020; Director at ARCA biopharma, Inc. in 2009 and 2011; Independent Director at Cascadian Therapeutics LLC from 2014 to 2018; Independent Director at Affymax, Inc. from 2011 to 2013; Director at Stanford Health Care-Stanford Hospital; Director at California Healthcare Institute; Director at California Institute for Regenerative Medicine from 2004 to 2006; Director at The Biotechnology Institute; VP-Product Development & Regulatory Affairs at Genentech, Inc. from 1992 to 1998; Executive VP & Head-Research & Development at Onyx Pharmaceuticals, Inc. from 2011 to 2012; Senior Vice President-Development at Innoviva, Inc. from 1998 to 2001; and Senior Vice President-Development at Theravance Biopharma Us LLC from 1998 to 2001.
Education includes undergraduate degree from Haverford College and doctorate from Yale School of Medicine.